These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. Comparative Effectiveness of Bladder-preserving Tri-modality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer. Royce TJ; Feldman AS; Mossanen M; Yang JC; Shipley WU; Pandharipande PV; Efstathiou JA Clin Genitourin Cancer; 2019 Feb; 17(1):23-31.e3. PubMed ID: 30482661 [TBL] [Abstract][Full Text] [Related]
16. The Effect of Tri-Modality Therapy with Bladder Preservation for Selective Muscle-Invasive Bladder Cancer. Zhiyu Z; Qi Z; Zhen S; Jun O; Jianglei Z Technol Cancer Res Treat; 2021; 20():15330338211062323. PubMed ID: 34816789 [No Abstract] [Full Text] [Related]
17. Contemporary and Emerging Approaches to Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer. Konieczkowski DJ; Efstathiou JA; Mouw KW Hematol Oncol Clin North Am; 2021 Jun; 35(3):567-584. PubMed ID: 33958151 [TBL] [Abstract][Full Text] [Related]
18. Trimodality therapy for bladder cancer: modern management and future directions. Pham A; Ballas LK Curr Opin Urol; 2019 May; 29(3):210-215. PubMed ID: 30855374 [TBL] [Abstract][Full Text] [Related]
19. Bladder sparing surgery in high-grade bladder cancer. Yakovlev PG; Klyushin DA; Vereshchako RI Exp Oncol; 2019 Jun; 41(2):160-165. PubMed ID: 31262149 [TBL] [Abstract][Full Text] [Related]
20. Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials. Arcangeli G; Strigari L; Arcangeli S Crit Rev Oncol Hematol; 2015 Sep; 95(3):387-96. PubMed ID: 25934521 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]